Save to Existing Project
Save to a New Project
Yeda R&D Co. Ltd
Abstract ID: 1280
Anti-inflammatory agents that modulate the inflammatory response were found to be effective in a wide variety of pathological conditions. Anti-inflammatory agents are usually classified as steroidal or glucocorticoids...
Anti-inflammatory agents that modulate the inflammatory response were found to be effective in a wide variety of pathological conditions. Anti-inflammatory agents are usually classified as steroidal or glucocorticoids and nonsteroidal anti-inflammatory agents (NSAIDs). The glucocorticoids are powerful anti-inflammatory agents but their chronic administration often leads to high toxicity.
Therefore, it would be highly desirable to provide new NSAIDs that could serve as alternatives to current anti-inflammatory drugs.
The most advanced new chemical entity (OA-1) derived from the outlined technology has been designed to treat psoriasis and other inflammatory skin diseases. The therapeutic effects of this molecule are equivalent to those produced by glucocorticoids but without the associated side effects.
The pathogenesis of immunologically-mediated inflammation disorders is tightly linked to the activation of T-cell lymphocytes. The mechanism of action of OA-1 involves the blockade of T-cell anti-inflammatory cytokine secretion, including IFNgamma and TNFalpha. This drug, administered topically as an emulsion in a balanced salt solution, has been shown to be effective in animal models of delayed hypersensitivity and in a model of psoriasis in which the disease is expressed in human psoriatic skin transplanted onto SCID mice. Other animal studies showed efficacy in other inflammatory models such as Adjuvant-Arthritis. Toxicology studies in preparation for human phase I trials are at an advanced stage.
We have elucidated oleyl alcohol with anti-inflammatory effects that may be chemically tailored for particular medical applications.
OA is suitable for treatment of psoriasis and other inflammatory skin problems. Please enquire quoting reference no. 1280 regarding licensing or codevelopment partnerships.
Last Updated May 2015